S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

NASDAQ:ANAB - AnaptysBio Stock Price, Forecast & News

$15.75
-0.41 (-2.54 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
$15.37
Now: $15.75
$15.90
50-Day Range
$14.00
MA: $15.25
$16.56
52-Week Range
$10.00
Now: $15.75
$83.10
Volume526,702 shs
Average Volume539,733 shs
Market Capitalization$427.34 million
P/E RatioN/A
Dividend YieldN/A
Beta1.19
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ANAB
CUSIPN/A
Phone858-362-6295

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5 million
Book Value$18.18 per share

Profitability

Net Income$-61,660,000.00

Miscellaneous

Employees78
Market Cap$427.34 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive ANAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.


AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

How were AnaptysBio's earnings last quarter?

AnaptysBio Inc (NASDAQ:ANAB) issued its quarterly earnings results on Friday, November, 8th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.09) by $0.06. During the same period last year, the business posted ($0.66) EPS. View AnaptysBio's Earnings History.

When is AnaptysBio's next earnings date?

AnaptysBio is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for AnaptysBio.

What price target have analysts set for ANAB?

9 brokers have issued twelve-month price objectives for AnaptysBio's stock. Their forecasts range from $12.00 to $140.00. On average, they expect AnaptysBio's share price to reach $71.29 in the next twelve months. This suggests a possible upside of 352.6% from the stock's current price. View Analyst Price Targets for AnaptysBio.

What is the consensus analysts' recommendation for AnaptysBio?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AnaptysBio.

Has AnaptysBio been receiving favorable news coverage?

Headlines about ANAB stock have been trending very negative on Monday, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AnaptysBio earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for AnaptysBio.

Are investors shorting AnaptysBio?

AnaptysBio saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 4,420,000 shares, an increase of 11.3% from the January 15th total of 3,970,000 shares. Based on an average trading volume of 999,800 shares, the short-interest ratio is currently 4.4 days. Currently, 18.1% of the company's stock are short sold. View AnaptysBio's Current Options Chain.

Who are some of AnaptysBio's key competitors?

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include Editas Medicine (EDIT), ImmunoGen (IMGN), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Baidu (BIDU), Baozun (BZUN), Crispr Therapeutics (CRSP), Momo (MOMO) and bluebird bio (BLUE).

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the folowing people:
  • Mr. Hamza Suria, Pres, CEO & Director (Age 43)
  • Mr. Dominic G. Piscitelli M.B.A., CPA, Chief Financial Officer (Age 44)
  • Prof. Marco Londei, Chief Medical Officer (Age 62)
  • Mr. Eric J. Loumeau, Gen. Counsel (Age 56)
  • Dr. Hemant Kumar, Sr. VP of Manufacturing

When did AnaptysBio IPO?

(ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are AnaptysBio's major shareholders?

AnaptysBio's stock is owned by a variety of of retail and institutional investors. Top institutional investors include EcoR1 Capital LLC (7.25%), State Street Corp (7.17%), Tang Capital Management LLC (6.80%), Boxer Capital LLC (4.79%), Perceptive Advisors LLC (3.69%) and BVF Inc. IL (3.46%). Company insiders that own AnaptysBio stock include Dominic Piscitelli, Hamza Suria, Marco Londei and Nicholas Lydon. View Institutional Ownership Trends for AnaptysBio.

Which major investors are selling AnaptysBio stock?

ANAB stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and SG Americas Securities LLC. Company insiders that have sold AnaptysBio company stock in the last year include Hamza Suria and Marco Londei. View Insider Buying and Selling for AnaptysBio.

Which major investors are buying AnaptysBio stock?

ANAB stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Tang Capital Management LLC, Boxer Capital LLC, Perceptive Advisors LLC, State Street Corp, BVF Inc. IL, Krensavage Asset Management LLC and Broadfin Capital LLC. View Insider Buying and Selling for AnaptysBio.

How do I buy shares of AnaptysBio?

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $15.75.

How big of a company is AnaptysBio?

AnaptysBio has a market capitalization of $427.34 million and generates $5 million in revenue each year. The biotechnology company earns $-61,660,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. AnaptysBio employs 78 workers across the globe.View Additional Information About AnaptysBio.

What is AnaptysBio's official website?

The official website for AnaptysBio is http://www.anaptysbio.com/.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]


MarketBeat Community Rating for AnaptysBio (NASDAQ ANAB)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  309 (Vote Outperform)
Underperform Votes:  237 (Vote Underperform)
Total Votes:  546
MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote "Outperform" if you believe ANAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: Monthly Dividend Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel